Value-Added Medicines

Coherus BioSciences says that it will work closely with the US Food and Drug Administration and the unnamed third-party filler to obtain approval for its proposed version of Neulasta Onpro on-body injector “as quickly as possible.”

Now in its tenth year, the Global Generics & Biosimilars Awards has received a record-breaking number of entries in 2023. Judges are now evaluating the nominees ahead of our awards ceremony on Wednesday 25 October at the Hotel Porta Fira in Barcelona.

After launching the Uzedy long-acting formulation of risperidone in partnership with MedinCell earlier this year, Teva has stressed the “really exciting” product profile of another long-acting antipsychotic from the partnership, olanzapine, while discussing how it will avoid the safety pitfalls of legacy products in the space.

Generics Bulletin previews the most notable and anticipated events for September 2023.

Outlook Therapeutics has received a CRL from the US FDA over its application for an ophthalmic formulation of bevacizumab. The company says it is working with the agency to address the various issues raised.

There is now just over a week to go until the final deadline for entries to the Global Generics & Biosimilars Awards 2023.

Viatris and Mapi have moved a step closer to realizing the US launch of their 505(b)(2) once- monthly glatiramer acetate product, a follow-on to Teva’s Copaxone treatment for multiple sclerosis.

Henlius has successfully established the safety and preliminary efficacy of its ophthalmology-indicated bevacizumab biosimilar HLX04-O in Phase I/II trials.

Just one month remains for contenders to submit their entries for consideration in the Global Generics & Biosimilars Awards 2023.

This article compiles all of the data from Generics Bulletin’s 2023 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.

In the third part of this year’s Generics Bulletin Top 50, we look at how various increases and declines for companies at the bottom of our table have affected their positions in the ranking.

In the second part of Generics Bulletin’s Top 50, we look at the mid-table players and how they have shifted positions this year.

In a year that has seen significant changes throughout our generics and biosimilars industry ranking, the top 10 has welcomed two Indian off-patent leaders after two other firms dropped out of the top table. We delve into what has changed in the first instalment of this year’s Generics Bulletin Top 50.

Generics Bulletin previews the most notable and anticipated events for August 2023.

Generics Bulletin previews the most notable and anticipated events for July 2023.

With entries currently open for the Global Generics & Biosimilars Awards 2023 – which will take place on Wednesday 25 October at the Hotel Porta Fira in Barcelona – we talk through the categories that companies can enter, tips to make entries stand out, as well as the benefits of entering and attending the awards.